Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 276-280

  Panara, Maria R ^a   Renda, Giulia ^a   Sciulli, Maria G ^a   Santini, Giovanna ^a   Giamberardino, Maria Di ^a   Rotondo, Maria T ^a   Tacconelli, Stefania ^a   Seta, Francesca ^a   Patrono, Carlo ^a   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; LIPOPOLYSACCHARIDE; MELOXICAM; PLACEBO; PROSTAGLANDIN E2; THROMBOXANE B2;

ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INHIBITION; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MONOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE;

ADULT; BLOOD PLATELETS; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MONOCYTES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THIAZINES; THIAZOLES; THROMBOXANE B2;

EID: 0033045831     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Allison MC, Howatson AG, Torrance CJ, Lee FD and Russell R (1992) Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 327:749-754.
2. Churchill L, Graham AG, Shih CK, Pauletti D, Farina PB and Grob PM (1996) Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 4:125-135.
3. 2α in human urine. J Endocrinol Invest 2:173-182.
4. Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C and Patrignani P (1995) Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther 58:335-341.
5. Cryer B and Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used non steroidal anti-inflammatory drugs. Am J Med 104:413-421.
6. De Lean A, Munson PJ and Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol 235:E97-E102.
7. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Bégaud B, Isomaki H, Littlejohn G, Mau J and Papazoglou S, on behalf of the SELECT study group (1998) Improvement in gastrointestinal tolerability of the selective COX-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large Scale Evaluation of COX Inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 37:946-961.
8. Distel M, Mueller C, Bluhmki E and Fries J (1996) Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol 35(Suppl 1):68-77.
9. Douthwaite AH and Lintott GAM (1938) Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 2:1222-1224.
10. Engelhardt G, Bogel R, Schnitzler C and Utzmann R (1996) Meloxicam: Influence on arachidonic acid metabolism (part I, in vitro findings). Biochem Pharmacol 51:21-28.
11. Engelhardt G, Homma D, Schlegel K, Utzmann R and Schnitzler C (1995) Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm Res 44:423-433.
12. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG and Agostinis L (1998) Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolac, other NSAIDs, calcium antagonists and other antihypertensive drugs. Arch Intern Med 158:33-39.
13. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Bégaud B, Dequeker J, Isomaki H, Littlejohn G, Mau J, Papazoglou S, and the International Melissa Study Group (1998) Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 37:937-945.
14. Henry D, Lim L L-Y, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S and Fries JT (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ 312:1563-1566.
15. Laneuville O, Breuer DK, De Witt DL, Funk CD and Smith WL (1994) Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271:927-934.
16. Langman MJS, Well J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP and Colin-Jones DG (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075-1078.
17. Meade EA, Smith WL and DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 288:6610-6614.
18. Mitchell JA, Akarascereenont P, Theimermann C, Flower RJ and Vane JR (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693-11697.
19. O'Banion MK, Winn VD and Yung DA (1992) cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Aci USA 88:4888-4892.
20. Pairet M, van Ryn H, Schierok H, Mauz A, Trummlitz G and Engelhardt G (1998) Differential inhibition of cyclooxygenase-1 and -2 by meloxicam and 4'-isomer. Inflamm Res 47:270-276.
21. Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, di Giamberardino M, Cipollone F, Cuccurullo F, Patrono C and Patrignani P (1995) Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methane-sulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 116:2429-2434.
22. Panara MR, Padovano R, Sciulli MG, Santini G, Renda G, Rotondo MT, Pace A, Patrone C and Patrignani P (1998) Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in man. Clin Pharmacol Ther 63:672-681.
23. Patrignani P, Filabozzi P and Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366-1372.
24. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J and Patrono C (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human whole blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1705-1712.
25. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G and Patrono C (1997) Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48:623-631.
26. 2 production in healthy subjects. Thromb Res 17:317-327.
27. Patrono C, Ciabattoni G, Patrignani P, Filabozzi P, Catella F, Davum G and Forni L (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72:1177-1184.
28. Riendeau D, Percival MD, Boyce S, Briedeau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret J-P, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Xu L, Young RN, Zamboni R, Prasit P and Chan C-C (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121:105-117.
29. Smith WL, Garavito RM and DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. J Biol Chem 271:33157-33160.
30. Stichtenoth DO, Wagner B and Frolich JC (1997) Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Invest Med 45:44-49.
31. Swinney DC, Mak AY, Barnett J and Ramesha CS (1997) Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J Biol Chem 272:12393-12398.
32. Turek D, Roth W and Busch U (1996) A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 35 (Suppl 1):13-16.
33. Turck D, Su C, Heinzel G, Busch U, Bluhmki E and Hoffmann J (1997) Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 51:421-425.
34. Vane JR (1971) Inhibition of prostaglandins as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
35. Vane JR (1994) Towards a better aspirin. Nature (London) 367:215-216.